HC Wainwright began coverage on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report published on Thursday morning, Benzinga reports. The brokerage issued a buy rating and a $8.00 target price on the stock.
A number of other brokerages have also commented on OTLK. Ascendiant Capital Markets started coverage on Graham in a research note on Monday, April 22nd. They set a buy rating and a $1.59 price target on the stock. CIBC reaffirmed a hold rating and issued a $3.00 price objective on shares of Information Services Group in a research note on Thursday, May 16th. Oppenheimer began coverage on Outlook Therapeutics in a research note on Thursday, May 16th. They issued an outperform rating and a $12.00 price objective on the stock. Finally, ValuEngine raised XPO Logistics from a strong sell rating to a sell rating in a research note on Thursday, April 4th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $9.00.
Shares of OTLK stock opened at $2.45 on Thursday. The company’s 50-day moving average price is $2.15. Outlook Therapeutics has a 12 month low of $0.85 and a 12 month high of $10.96. The firm has a market capitalization of $63.82 million, a price-to-earnings ratio of -0.23 and a beta of -0.86.
An institutional investor recently bought a new position in Outlook Therapeutics stock. Chicago Capital LLC acquired a new position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 19,450 shares of the company’s stock, valued at approximately $40,000. Chicago Capital LLC owned about 0.07% of Outlook Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 0.87% of the company’s stock.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Further Reading: Technical Indicators – What is a Golden Cross?
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.